AstraZeneca: The Phase III clinical trial results of Itraconazole tablets are published in "The Lancet Respiratory Medicine"

Aussiekang's announcement: Recently, the company's innovative drug, Erlotinib tablets, was published in a top international medical journal, "The Lancet Respiratory Medicine," with the results of its Phase III clinical trial. Erlotinib tablets are a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used as first-line or second-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.